Media

KDA develops innovative solutions for global markets that drive health system transformation. To contact us, write to info@groupekda.ca

KDA GROUP ANNOUNCES THE DEVELOPMENT OF MEDHERIZE, A NEW CLINICAL MANAGEMENT SOLUTION FOR SPECIALIZED MEDICATIONS FOR BREAST CANCER

12 June 2024

Thetford Mines, Quebec – June 12, 2024 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”), a leader in healthcare and medical technology innovation, is proud to announce the launch of Medherize, its revolutionary new platform dedicated to the clinical management of patients requiring specialized medications. This pioneering project particularly focuses on CDK 4/6 inhibitors used in the treatment of breast cancer, with the objective of ensuring optimal and personalized patient follow-up.

Learn more

KDA GROUP ANNOUNCES RESULTS OF SHAREHOLDERS’ ANNUAL GENERAL AND SPECIAL MEETING

17 May 2024

Thetford Mines, Quebec – May 17, 2024 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) announces the voting results of the annual general and special meeting of shareholders (the “Meeting”) held yesterday, in Longueuil.

Learn more

ADHERIZE+ PLATFORM UPDATE

21 March 2024

Thetford Mines, Quebec – March 21, 2024 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is pleased to announce an update in the development and use of its Adherize+ platform. With the aim of assisting and improving the follow-up of hormone-dependent breast cancer patients taking oral CDK 4/6 inhibitor therapy, the Corporation, through its Adherize+ platform, will develop the monitoring and follow-up algorithm for these patients in collaboration with oncology physicians and pharmacists

Learn more

KDA GROUP COMPLETES DEBT SETTLEMENT

29 February 2024

Thetford Mines, Quebec – February 29, 2024 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is pleased to announce that the debt settlement previously announced in its press release dated February 22, 2024 has been completed and the Corporation settled indebtedness to a creditor totalling $1,236,398 in exchange for the issuance of 4,000,000 Class A Shares of KDA (“Common shares”) at a price of $0.309 per Common share (the “Debt Settlement”).

Learn more

KDA GROUP ANNOUNCES THE APPOINTMENTS OF YVES MARMET AS GENERAL MANAGER AND CHIEF TECHNOLOGY OFFICER AND MARIE-HÉLÈNE PINARD AS CHIEF OPERATION OFFICER OF ITS SUBSIDIARY GROUPE TECHNOLOGIQUE KDA, AND A DEBT SETTLEMENT

22 February 2024

Thetford Mines, Quebec – February 22, 2024 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is pleased to announce the appointments of Mr. Yves Marmet as General Manager and Chief Technology Officer and Ms. Marie-Hélène as Chief Operating Officer of its subsidiary Groupe Technologique KDA Inc. effective immediately.

Learn more
1 2 3 6